An FDA Panel Just Backed BPC-157 and KPV. The Evidence Hasn’t Caught Up.

Key Takeaways:

• On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6 to recommend adding BPC-157 to the list of bulk substances that compounding pharmacies may legally use, and gave KPV a similarly narrow yes — both votes cast against the recommendation of the agency’s own scientific reviewers.
• The vote is advisory only: before anything changes, the FDA must accept the recommendation and complete formal notice-and-comment rulemaking, a process that typically takes twelve to twenty-four months, so nothing about a pharmacy’s legal options changed the day of the vote.
• The human evidence remains thin. A 2025 systematic review of BPC-157 found 35 of its 36 studies were done in animals or cells and just one in people — an uncontrolled series of twelve patients — while the FDA’s reviewers summarized KPV’s clinical file as “no human data at all.”

On July 23, 2026, an FDA advisory panel did something it rarely does: it overruled its own agency’s scientists. The Pharmacy Compounding Advisory Committee voted 8–6 to recommend that two compounded peptides — BPC-157 and KPV — be added to the Section 503A list of bulk substances that pharmacies are permitted to use, and handed KPV a similarly slim yes. If you follow the peptide world, that reads like a green light, and it is worth slowing down before treating it as one. The committee only recommends. For anything to actually change, the FDA has to accept the recommendation and then walk it through formal notice-and-comment rulemaking, which usually runs a year to two. So the day of the vote, a pharmacy’s legal options were exactly what they had been the day before. Three separate ideas get compressed into that headline and are worth pulling back apart: “a panel recommended it,” “it may become legal to compound,” and “it works.” This vote spoke only to the first, and only provisionally.

So what do we actually know about these molecules? Less than the enthusiasm implies. BPC-157 — the initials stand for body protection compound — is a synthetic fragment related to a protein found in gastric juice, and it has been studied for gut and connective-tissue healing for years, almost entirely in the laboratory. A 2025 systematic review screened 544 papers and included 36; of those, 35 were animal or cell studies, and exactly one involved humans: a retrospective series of twelve patients with knee pain, with no control group, no blinding, and no imaging. The reviewers turned up essentially no clinical safety data. KPV is more mechanistically elegant. It is a three–amino-acid tail — lysine, proline, valine — clipped from the end of the hormone alpha-melanocyte-stimulating hormone, and in preclinical models it damps inflammation, apparently by inhibiting interleukin-1β signaling and doing so without even needing to dock on a melanocortin receptor. But “in preclinical models” is the load-bearing phrase, and the FDA’s reviewers were blunt about the rest, characterizing KPV’s human evidence as “no human data at all.”

Should you try compounded peptides while the evidence is still this thin?

That is the honest question, and the answer is a posture rather than a verdict. Promising results in a dish or a rodent are a reason to run a proper trial, not a reason to assume a benefit in people — medicine’s history is crowded with compounds that healed animals and then did nothing for patients, or quietly harmed them once studied at scale. If you are weighing a peptide, the defensible stance is informed caution. Understand that you would be an early adopter of something whose benefits are still hypothesized and whose long-term safety is genuinely unknown; insist on a licensed compounding pharmacy and a physician who will actually monitor you rather than a mail-order vial; and keep in mind that a narrow committee vote, taken over the objection of the agency’s scientists and by panelists some of whom were reported to have ties to the peptide industry, reflects market demand at least as much as it reflects settled evidence. Access is moving faster than proof here. That is not a cue for cynicism or for hype — it is a cue to keep asking the only question that matters: what, specifically, do we know, and how well do we know it?

References:

1. Vasireddi, N., Hahamyan, H., Salata, M. J., Karns, M., Calcei, J. G., Voos, J. E., et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal, 21(4), 15563316251355551.
2. Getting, S. J., Schiöth, H. B., & Perretti, M. (2003). Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. The Journal of Pharmacology and Experimental Therapeutics, 306(2), 631-637.
3. Dalmasso, G., Charrier-Hisamuddin, L., Nguyen, H. T. T., Yan, Y., Sitaraman, S., & Merlin, D. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166-178.
4. U.S. Food and Drug Administration. (2026). July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration.